Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26277055 | 1.00 | CTSK (0.48) | CTSKEPHX1CA1CA2CTSS | |
| SCHEMBL28273790 | 1.00 | CTSK (0.48) | CTSKEPHX1CA1CA2CTSS | |
| SCHEMBL25526269 | 1.00 | CTSK (0.48) | CTSKEPHX1CA1CA2CTSS | |
| SCHEMBL28273791 | 1.00 | CTSK (0.48) | CTSKEPHX1CA1CA2CTSS | |
| SCHEMBL25526281 | 1.00 | CTSK (0.48) | CTSKEPHX1CA1CA2CTSS | |
| SCHEMBL25526283 | 1.00 | CTSK (0.48) | CTSKEPHX1CA1CA2CTSS | |
| SCHEMBL30601914 | 1.00 | CTSK (0.48) | CTSKEPHX1CA1CA2CTSS | |
| SCHEMBL30219212 | 1.00 | CTSK (0.48) | CTSKEPHX1CA1CA2CTSS | |
| SCHEMBL28854991 | 1.00 | CTSK (0.48) | CTSKEPHX1CA1CA2CTSS | |
| SCHEMBL25526130 | 1.00 | CTSK (0.48) | CTSKEPHX1CA1CA2CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| CN-115175735-B | Antiviral compounds | 吉利德科学公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230151049-A1 | Compounds Useful in HIV Therapy | VIIV HEALTHCARE COMPANY (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151049-A1 | Compounds Useful in HIV Therapy | VIIV HEALTHCARE COMPANY (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4126888-A1 | COMPOUNDS USEFUL IN HIV THERAPY | VIIV Healthcare Company (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4106877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220356196-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2022-11-10 | — | — | US | disclosed |
| WO-1993007853-A1 | INHIBITION OF ODOR FORMATION AND BACTERIAL GROWTH | MONELL CHEMICAL SENSES CENTER (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | CTSK 1828/4885EPHX1 2027/4885CA1 4866/4885 |
| US-20220356196-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | CTSK 1828/4885EPHX1 2027/4885CA1 4866/4885 |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | CTSK 4185/4885EPHX1 1627/4885CA1 4447/4885 |
| US-20230151049-A1 | Compounds Useful in HIV Therapy | CCR5, CD4, NPC1 | CTSK 1780/4885EPHX1 1532/4885CA1 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.